GlassScriptPhysician profile
Clifford Risk
NPI 1013029651
$8,225.72
in general payments reported to CMS, 2019-2025
16 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $570 · 2021: $830 · 2022: $1,284 · 2023: $1,669 · 2024: $1,417 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,276 · Education: $66.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,275.70 |
| Education | $66.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,921.48 | 2019-2025 | Tezspire, Fasenra, Farxiga |
| Glaxosmithkline, LLC. | $992.34 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $772.03 | 2019-2025 | Dupixent |
| Amgen INC. | $555.77 | 2019-2025 | Tezspire |
| Genzyme Corporation | $301.54 | 2021-2025 | |
| Electromed, INC. | $217.00 | 2019-2025 | Smartvest |
| Radius Health, INC. | $145.44 | 2019-2020 | |
| Mylan Specialty L.P. | $133.50 | 2019-2024 | Yupelri |
| Insmed, INC. | $82.45 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $21.00 | 2019 | |
| Viatris Specialty LLC | $19.84 | 2025 | Yupelri |
| Idorsia Pharmaceuticals US INC | $14.65 | 2023 | Quviviq |
| Pfizer INC. | $14.31 | 2024 | |
| Circassia INC. | $12.16 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.31 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifford Risk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.